Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Lymphoma, Leukemia |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 11/16/2018 |
| Start Date: | July 11, 2007 |
| End Date: | July 2019 |
| Contact: | Farhad Ravandi-Kashani, MD |
| Phone: | 713-745-0394 |
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma
The goal of this clinical research study is to learn the effectiveness of intensive
chemotherapy given in combination with nelarabine (followed by maintenance therapy) in the
treatment of patients with T cel ALL and T cell lymphoblastic lymphoma. The safety of this
treatment will also be studied.
This is an investigational study. All of the drugs used in this study are FDA approved and
commercially available. Their use together in this study is investigational and for use in
research only. Up to 130 patients will take part in this study. All will be enrolled at MD
Anderson.
chemotherapy given in combination with nelarabine (followed by maintenance therapy) in the
treatment of patients with T cel ALL and T cell lymphoblastic lymphoma. The safety of this
treatment will also be studied.
This is an investigational study. All of the drugs used in this study are FDA approved and
commercially available. Their use together in this study is investigational and for use in
research only. Up to 130 patients will take part in this study. All will be enrolled at MD
Anderson.
Inclusion Criteria:
1. Previously untreated T cell ALL including T cell lymphoblastic lymphoma. Failure to
one induction course of chemotherapy are eligible. Patients in CR after are also eligible.
2. ECOG performance status less than or equal to 3.
3. Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement
by tumor when an upper limit of 5.0 mg/dL is acceptable. SGOT or SGPT less than or
equal to 4 x ULN.
4. Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement
by tumor when an upper limit of 2.5 mg/dL is acceptable.
Exclusion Criteria:
1) Pregnant or nursing women
We found this trial at
1
site
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials
